Patents by Inventor Karina Thorn
Karina Thorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230416404Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.Type: ApplicationFiled: September 6, 2023Publication date: December 28, 2023Inventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
-
Patent number: 11787874Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.Type: GrantFiled: November 15, 2018Date of Patent: October 17, 2023Assignee: Novo Nordisk A/SInventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
-
Publication number: 20230058721Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.Type: ApplicationFiled: November 10, 2021Publication date: February 23, 2023Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
-
Patent number: 11220554Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.Type: GrantFiled: January 29, 2021Date of Patent: January 11, 2022Assignee: Novo Nordisk A/SInventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
-
Publication number: 20210388114Abstract: The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.Type: ApplicationFiled: February 1, 2018Publication date: December 16, 2021Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou, Prafull S. Gandhi
-
Publication number: 20210238306Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.Type: ApplicationFiled: January 29, 2021Publication date: August 5, 2021Inventors: Karina Thorn, Bjarne Gram Hansen, Laust Bruun Johnsen, Mikkel Nors Harndahl, Zhiru Yang, Henrik Oestergaard, Per J. Greisen, Eva Johansson, Morten Groenbech Rasch, Jianhe Chen, Anders Svensson, Haisun Zhu, Rong Zhou
-
Publication number: 20210054097Abstract: The application relates to unique FX binding molecules, such as antibodies and fragments thereof which are useful in the treatment of haemophilia.Type: ApplicationFiled: November 15, 2018Publication date: February 25, 2021Inventors: Jacob Lund, Karina Thorn, Mikkel Nors Harndahl, Marie-Ange Buyse, Evelyn De Tavernier, Soren Steffensen
-
Patent number: 10584147Abstract: The present invention provides a fusion compound comprising a procoagulant compound and an immunoglobulin constant region or a portion thereof and methods of making and using the fusion compound. The fusion compounds of the present disclosure are useful for the treatment of coagulation disorders, such as hemophilia. In some aspects, the invention includes a method of reducing or preventing aggregates which comprise a procoagulant compound comprising fusing the procoagulant compound to an immunoglobulin constant region or a portion thereof wherein the procoagulant compound comprises an amino acid sequence. In another embodiment, the fusion compound forms less aggregates compared to a compound consisting of the procoagulant compound.Type: GrantFiled: November 7, 2014Date of Patent: March 10, 2020Assignee: Biovertiv Therapeutics Inc.Inventor: Karina Thorn
-
Patent number: 9486507Abstract: The present invention provides pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. The present disclosure further provides conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates of the present disclosure are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. The present disclosure further provides methods of using and making the conjugates.Type: GrantFiled: June 9, 2012Date of Patent: November 8, 2016Assignee: Biogen MA Inc.Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo
-
Publication number: 20160289273Abstract: The present invention provides a fusion compound comprising a procoagulant compound and an immunoglobulin constant region or a portion thereof and methods of making and using the fusion compound. The fusion compounds of the present disclosure are useful for the treatment of coagulation disorders, such as hemophilia. In some aspects, the invention includes a method of reducing or preventing aggregates which comprise a procoagulant compound comprising fusing the procoagulant compound to an immunoglobulin constant region or a portion thereof wherein the procoagulant compound comprises an amino acid sequence. In another embodiment, the fusion compound forms less aggregates compared to a compound consisting of the procoagulant compound.Type: ApplicationFiled: November 7, 2014Publication date: October 6, 2016Applicant: Biogen MA Inc.Inventor: Karina THORN
-
Publication number: 20140303084Abstract: Provided are pro-coagulant compounds (e.g., pro-coagulant peptides or peptide derivatives) and methods of using and making those compounds. Further provided are conjugates between a pro-coagulant compound of the present disclosure (e.g., pro-coagulant peptide or peptide derivative) and a polypeptide selected from FIX, FVIIa, FVIII, and platelet targeting moieties (e.g., PDG-13), wherein the compound is linked to the polypeptide optionally via a linker. The compounds and conjugates are useful for the treatment of coagulation disorders, such as hemophilia A and hemophilia B. Further provided are methods of using and making the conjugates.Type: ApplicationFiled: June 9, 2012Publication date: October 9, 2014Applicant: Biogen IDEC MA Inc.Inventors: Karina Thorn, Garabet G. Toby, Adam R. Mezo